Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €28.82 EUR
Change Today -0.152 / -0.52%
Volume 0.0
ZEGA On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 2:16 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc-spons adr (ZEGA) Snapshot

Open
€28.30
Previous Close
€28.97
Day High
€28.82
Day Low
€28.30
52 Week High
04/23/15 - €34.15
52 Week Low
08/24/15 - €25.92
Market Cap
72.8B
Average Volume 10 Days
49.8
EPS TTM
--
Shares Outstanding
2.5B
EX-Date
08/12/15
P/E TM
--
Dividend
€0.90
Dividend Yield
4.30%
Current Stock Chart for ASTRAZENECA PLC-SPONS ADR (ZEGA)

astrazeneca plc-spons adr (ZEGA) Details

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders; Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. It also engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Celgene Corporation, Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., Pharmacyclics Inc., and Janssen Research & Development, LLC., as well as a strategic collaboration with Isis Pharmaceuticals, Inc. to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. It also has a license from Heptares Therapeutics Ltd. to develop, manufacture, and commercialize the adenosine A2A receptor antagonist, HTL-1071. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

57,500 Employees
Last Reported Date: 03/10/15
Founded in 1992

astrazeneca plc-spons adr (ZEGA) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.1M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 1.7M GBP
Compensation as of Fiscal Year 2014.

astrazeneca plc-spons adr (ZEGA) Key Developments

AstraZeneca Announces Positive Results from RECAPTURE 1 and RECAPTURE 2

AstraZeneca announced positive results from RECAPTURE 1 and RECAPTURE 2, the pivotal Phase III studies evaluating the antibiotic, CAZ-AVI (ceftazidime-avibactam), as a treatment for adult hospitalised patients with complicated Urinary Tract Infections (cUTI), including pyelonephritis. CAZ-AVI consists of a cephalosporin (ceftazidime), an established treatment for serious bacterial infections, and a next generation non-beta lactam beta-lactamase inhibitor (avibactam). CAZ-AVI is being developed to treat a broad range of Gram-negative bacterial infections which are becoming increasingly resistant to antibiotics and pose a threat to public health. The addition of avibactam protects ceftazidime from being broken down by beta-lactamases that are produced by these resistant bacteria. The global RECAPTURE 1 and RECAPTURE 2 Phase III studies evaluated the safety and efficacy of CAZ-AVI, administered intravenously as a two-hour infusion (2000/500mg every 8 hours), compared to doripenem, administered intravenously as a 30-minute infusion (500mg every 8 hours), in hospitalised adult patients with cUTI, including pyelonephritis. Data from the studies were analysed as a single-pooled dataset with the agreement of the US FDA and the EMA. In the RECAPTURE 1 and RECAPTURE 2 Phase III studies, CAZ-AVI met the objective of statistical non-inferiority compared to doripenem for both the EMA primary and FDA co-primary endpoints. Additionally, for the EMA primary endpoint, CAZ-AVI was statistically superior (at the 5% level) to doripenem.

Daiichi Sankyo Enters into Licensing Agreement with AstraZeneca

Daiichi Sankyo Co. announced that it has been licensed to develop and sell a nasal spray-type live attenuated influenza vaccine in Japan. The Japanese drug maker concluded the licensing agreement with a subsidiary of AstraZeneca. The amount of the deal was not disclosed. After gaining regulatory approval in Japan, Daiichi Sankyo aims to start selling the vaccine as soon as possible.

Valeant Pharmaceuticals International, Inc. and Astrazeneca Enter Collaboration Agreement on Brodalumab

Valeant Pharmaceuticals International Inc. announced that its affiliate has entered into a collaboration agreement with AstraZeneca (AZN) under which Valeant was granted an exclusive license to develop and commercialize brodalumab. Brodalumab is an IL-17 receptor monoclonal antibody in development for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. Under the agreement, Valeant will hold the exclusive rights to develop and commercialize brodalumab globally, except in Japan and certain other Asian countries where rights are held by Kyowa Hakko Kirin Co. Ltd. under a prior arrangement with Amgen Inc. Valeant will assume all development costs associated with the regulatory approval for brodalumab. Regulatory submission in US and EU for brodalumab in moderate-to-severe psoriasis is planned for the fourth quarter of 2015. As per agreement terms, Valeant will make an up-front payment to AstraZeneca of $100 million, as well as additional pre-launch milestones of up to $170 million and further sales-related milestone payments of up to $175 million following launch. After approval, AstraZeneca and Valeant will share profits. The company said it expects the transaction to complete in the fourth quarter of 2015, subject to customary closing conditions, including Hart-Scott-Rodino anti-trust clearance.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEGA:GR €28.82 EUR -0.152

ZEGA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $141.74 USD +0.50
BASF SE €71.07 EUR +0.298
Biogen Inc $301.63 USD -2.58
Eli Lilly & Co $81.60 USD -0.21
Valeant Pharmaceuticals International Inc C$301.25 CAD -6.75
View Industry Companies
 

Industry Analysis

ZEGA

Industry Average

Valuation ZEGA Industry Range
Price/Earnings 67.5x
Price/Sales 3.2x
Price/Book 4.4x
Price/Cash Flow 67.5x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC-SPONS ADR, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.